Oncomed Pharmaceuticals Stock Price, News & Analysis (NASDAQ:OMED)

$4.07 0.15 (3.83 %)
(As of 12/13/2017 04:00 PM ET)
Previous Close$3.92
Today's Range$3.94 - $4.26
52-Week Range$2.91 - $10.89
Volume379,077 shs
Average Volume279,692 shs
Market Capitalization$175.65 million
P/E RatioN/A
Dividend YieldN/A
Beta2.8

About Oncomed Pharmaceuticals (NASDAQ:OMED)

Oncomed Pharmaceuticals logoOncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

Receive OMED News and Ratings via Email

Sign-up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OMED
CUSIPN/A
Phone650-995-8200

Debt

Debt-to-Equity RatioN/A
Current Ratio3.39%
Quick Ratio3.39%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.15 million
Price / Sales6.13
Cash FlowN/A
Price / CashN/A
Book Value($0.62) per share
Price / Book-6.56

Profitability

Trailing EPS($1.89)
Net Income$-103,100,000.00
Net Margins-298.57%
Return on EquityN/A
Return on Assets-48.03%

Miscellaneous

Employees122
Outstanding Shares37,860,000

Oncomed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions

What is Oncomed Pharmaceuticals' stock symbol?

Oncomed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."

How were Oncomed Pharmaceuticals' earnings last quarter?

Oncomed Pharmaceuticals Inc (NASDAQ:OMED) issued its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.13. The biopharmaceutical company had revenue of $5.11 million for the quarter, compared to the consensus estimate of $6.25 million. The company's revenue for the quarter was down 13.7% on a year-over-year basis. During the same period last year, the firm earned ($0.77) earnings per share. View Oncomed Pharmaceuticals' Earnings History.

When will Oncomed Pharmaceuticals make its next earnings announcement?

Oncomed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Oncomed Pharmaceuticals.

Where is Oncomed Pharmaceuticals' stock going? Where will Oncomed Pharmaceuticals' stock price be in 2017?

8 Wall Street analysts have issued 12-month price objectives for Oncomed Pharmaceuticals' shares. Their forecasts range from $4.00 to $10.00. On average, they anticipate Oncomed Pharmaceuticals' share price to reach $6.00 in the next year. View Analyst Ratings for Oncomed Pharmaceuticals.

What are Wall Street analysts saying about Oncomed Pharmaceuticals stock?

Here are some recent quotes from research analysts about Oncomed Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop antibody and other protein-based therapeutics. The company serves the healthcare industry and cancer therapy patients. OncoMed Pharmaceuticals, Inc. is based in Redwood City, United States. " (11/9/2017)
  • 2. Cantor Fitzgerald analysts commented, "Restructuring plan should lengthen cash runway by at least a year, and we view a focus on assets with potential milestone opportunities as a positive given." (4/25/2017)

Who are some of Oncomed Pharmaceuticals' key competitors?

Who are Oncomed Pharmaceuticals' key executives?

Oncomed Pharmaceuticals' management team includes the folowing people:

  • Paul J. Hastings, Chairman of the Board, Chief Executive Officer (Age 57)
  • Sunil Patel, Chief Financial Officer, Executive Vice President, Corporate Development and Finance and President (Age 45)
  • John A. Lewicki Ph.D., Executive Vice President - Research and Development (Age 64)
  • Austin Gurney Ph.D., Senior Vice President, Molecular and Cellular Biology (Age 51)
  • Tim Hoey Ph.D., Senior Vice President, Cancer Biology (Age 56)
  • Alicia J Hager J.D. Ph.D., Vice President, General Counsel (Age 46)
  • Jack W. Lasersohn J.D., Lead Independent Director (Age 62)
  • Perry A. Karsen, Director (Age 62)
  • Rick E. Winningham, Director (Age 57)
  • Elisha P. Gould III, Independent Director (Age 57)

Who owns Oncomed Pharmaceuticals stock?

Oncomed Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Adams Street Partners LLC (3.89%), Perceptive Advisors LLC (2.74%), Ameriprise Financial Inc. (2.41%), Candriam Luxembourg S.C.A. (0.98%), Iguana Healthcare Management LLC (0.92%) and Disciplined Growth Investors Inc. MN (0.83%). Company insiders that own Oncomed Pharmaceuticals stock include Alicia J Hager, Jack W Lasersohn, Jakob Dupont, John A Lewicki, Jonathan D Root, Paul J Hastings, Perry A Karsen, Sunil Patel and Timothy Hoey. View Institutional Ownership Trends for Oncomed Pharmaceuticals.

Who sold Oncomed Pharmaceuticals stock? Who is selling Oncomed Pharmaceuticals stock?

Oncomed Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Adams Street Partners LLC, Cannell Peter B & Co. Inc., Ameriprise Financial Inc., Iguana Healthcare Management LLC, Disciplined Growth Investors Inc. MN and Citadel Advisors LLC. Company insiders that have sold Oncomed Pharmaceuticals company stock in the last year include Alicia J Hager, John A Lewicki, Jonathan D Root, Paul J Hastings, Sunil Patel and Timothy Hoey. View Insider Buying and Selling for Oncomed Pharmaceuticals.

Who bought Oncomed Pharmaceuticals stock? Who is buying Oncomed Pharmaceuticals stock?

Oncomed Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Candriam Luxembourg S.C.A. and Hodges Capital Management Inc.. Company insiders that have bought Oncomed Pharmaceuticals stock in the last two years include Jack W Lasersohn and Perry A Karsen. View Insider Buying and Selling for Oncomed Pharmaceuticals.

How do I buy Oncomed Pharmaceuticals stock?

Shares of Oncomed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oncomed Pharmaceuticals' stock price today?

One share of Oncomed Pharmaceuticals stock can currently be purchased for approximately $4.07.

How big of a company is Oncomed Pharmaceuticals?

Oncomed Pharmaceuticals has a market capitalization of $175.65 million and generates $25.15 million in revenue each year. The biopharmaceutical company earns $-103,100,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Oncomed Pharmaceuticals employs 122 workers across the globe.

How can I contact Oncomed Pharmaceuticals?

Oncomed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected]


MarketBeat Community Rating for Oncomed Pharmaceuticals (OMED)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about Oncomed Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Oncomed Pharmaceuticals (NASDAQ:OMED) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.252.222.222.22
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$10.25$11.75$13.00
Price Target Upside: 37.30% upside134.55% upside173.89% upside272.49% upside

Oncomed Pharmaceuticals (NASDAQ:OMED) Consensus Price Target History

Price Target History for Oncomed Pharmaceuticals (NASDAQ:OMED)

Oncomed Pharmaceuticals (NASDAQ:OMED) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017SunTrust BanksReiterated RatingHold$4.00N/AView Rating Details
9/28/2017Jefferies GroupReiterated RatingBuy$5.00LowView Rating Details
9/19/2017Cantor FitzgeraldReiterated RatingHold$6.00LowView Rating Details
7/10/2017Piper Jaffray CompaniesSet Price TargetHold$5.00MediumView Rating Details
5/15/2017HC WainwrightLower Price TargetBuy -> Buy$9.00 -> $6.00LowView Rating Details
4/17/2017JMP SecuritiesDowngradeOutperform -> Market PerformLowView Rating Details
4/11/2017Leerink SwannBoost Price TargetMarket Perform$6.00 -> $10.00HighView Rating Details
4/11/2017BMO Capital MarketsDowngradeOutperform -> Market Perform$6.00HighView Rating Details
6/1/2016MizuhoLower Price TargetNeutral$45.00 -> $40.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Oncomed Pharmaceuticals (NASDAQ:OMED) Earnings History and Estimates Chart

Earnings by Quarter for Oncomed Pharmaceuticals (NASDAQ:OMED)

Oncomed Pharmaceuticals (NASDAQ OMED) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018($0.35)N/AView Earnings Details
11/2/2017Q3 2017($0.41)($0.28)$6.25 million$5.11 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.50)($0.40)$6.08 million$6.20 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.62)($0.61)$5.85 million$6.20 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.68)($0.60)$6.57 million$6.22 millionViewListenView Earnings Details
11/1/2016Q3($0.77)($0.77)$9.48 million$5.92 millionViewN/AView Earnings Details
8/9/2016Q216($0.81)($0.91)$8.09 million$6.67 millionViewN/AView Earnings Details
5/5/2016Q1($0.73)($0.90)$8.28 million$6.40 millionViewN/AView Earnings Details
3/10/2016Q4$0.41$1.50$44.55 million$6.80 millionViewListenView Earnings Details
11/5/2015Q315($0.80)($0.81)$5.84 million$4.70 millionViewListenView Earnings Details
8/10/2015Q215($0.49)($0.72)$13.78 million$4.70 millionViewListenView Earnings Details
5/7/2015Q115($0.35)($0.49)$15.35 million$9.70 millionViewN/AView Earnings Details
3/12/2015Q414($0.27)($0.50)$11.92 million$8.51 millionViewN/AView Earnings Details
11/4/2014($0.30)($0.18)$17.84 million$19.02 millionViewN/AView Earnings Details
8/7/2014Q214($0.03)($0.53)$21.28 million$6.00 millionViewN/AView Earnings Details
5/8/2014Q114($0.13)($0.47)$18.08 million$6.02 millionViewN/AView Earnings Details
3/18/2014Q4 13$0.15($0.15)$20.37 million$19.00 millionViewN/AView Earnings Details
11/12/2013Q3$0.12($0.15)ViewN/AView Earnings Details
9/3/2013Q2 2013($0.02)($0.83)$8.31 million$2.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Oncomed Pharmaceuticals (NASDAQ:OMED) Earnings Estimates

2017 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.76)($0.63)($0.68)
Q2 20173($0.65)($0.37)($0.47)
Q3 20173($0.56)($0.32)($0.42)
Q4 20173($0.49)($0.32)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Oncomed Pharmaceuticals (NASDAQ:OMED)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Oncomed Pharmaceuticals (NASDAQ OMED) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 32.80%
Institutional Ownership Percentage: 39.44%
Insider Trades by Quarter for Oncomed Pharmaceuticals (NASDAQ:OMED)
Insider Trades by Quarter for Oncomed Pharmaceuticals (NASDAQ:OMED)

Oncomed Pharmaceuticals (NASDAQ OMED) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/10/2017Alicia J HagerSVPSell1,248$4.24$5,291.52View SEC Filing  
10/10/2017Paul J HastingsCEOSell1,398$4.24$5,927.52View SEC Filing  
6/5/2017Perry A KarsenDirectorBuy10,000$3.46$34,600.00View SEC Filing  
5/26/2017Jonathan D RootDirectorSell13,880$3.71$51,494.80View SEC Filing  
5/25/2017Jack W LasersohnDirectorBuy34,614$3.37$116,649.18View SEC Filing  
5/23/2017Jack W LasersohnDirectorBuy20,000$3.55$71,000.00View SEC Filing  
5/19/2017Jonathan D RootDirectorSell7,487$3.70$27,701.90View SEC Filing  
5/16/2017Jack W LasersohnDirectorBuy23,507$3.49$82,039.43View SEC Filing  
4/4/2017Alicia J. HagerSVPSell4,316$9.06$39,102.96View SEC Filing  
4/4/2017Paul J. HastingsCEOSell6,473$9.06$58,645.38View SEC Filing  
4/4/2017Sunil PatelInsiderSell5,754$9.06$52,131.24View SEC Filing  
1/6/2017Paul J. HastingsCEOSell42,738$8.34$356,434.92View SEC Filing  
1/3/2017John A. LewickiEVPSell9,175$7.63$70,005.25View SEC Filing  
1/3/2017Timothy HoeySVPSell12,763$7.64$97,509.32View SEC Filing  
1/11/2016Jakob DupontSVPSell2,500$20.01$50,025.00View SEC Filing  
1/7/2016Alicia J. HagerVPSell1,623$22.28$36,160.44View SEC Filing  
1/7/2016John A. LewickiEVPSell2,162$22.28$48,169.36View SEC Filing  
1/6/2016Paul J. HastingsCEOSell2,412$22.28$53,739.36View SEC Filing  
11/27/2015Alicia J. HagerVPSell1,800$23.14$41,652.00View SEC Filing  
10/27/2015Alicia J. HagerVPSell5,400$21.00$113,400.00View SEC Filing  
10/26/2015Austin GurneyInsiderSell14,000$20.00$280,000.00View SEC Filing  
10/26/2015Jakob DupontSVPSell5,000$20.00$100,000.00View SEC Filing  
9/30/2015Jack W. LasersohnDirectorBuy11,210$16.01$179,472.10View SEC Filing  
9/29/2015Jack W. LasersohnDirectorBuy3,140$14.15$44,431.00View SEC Filing  
9/28/2015Jack W. LasersohnDirectorBuy10,000$14.74$147,400.00View SEC Filing  
7/10/2015Jakob DupontSVPSell2,500$20.13$50,325.00View SEC Filing  
7/6/2015Jakob DupontSVPSell2,500$21.22$53,050.00View SEC Filing  
6/29/2015Alicia J HagerVPSell1,800$22.67$40,806.00View SEC Filing  
6/22/2015Timothy HoeySVPSell5,000$26.07$130,350.00View SEC Filing  
6/16/2015John A LewickiEVPSell17,000$25.07$426,190.00View SEC Filing  
6/15/2015John A LewickiEVPSell8,500$24.92$211,820.00View SEC Filing  
5/27/2015Alicia J HagerVPSell1,800$23.07$41,526.00View SEC Filing  
5/18/2015Austin GurneyInsiderSell4,000$22.48$89,920.00View SEC Filing  
4/27/2015Alicia J HagerVPSell1,800$25.65$46,170.00View SEC Filing  
4/27/2015Timothy HoeySVPSell6,887$25.65$176,651.55View SEC Filing  
4/17/2015Austin GurneyInsiderSell4,000$25.51$102,040.00View SEC Filing  
4/10/2015Jakob DupontSVPSell1,500$26.51$39,765.00View SEC Filing  
4/2/2015John A LewickiEVPSell17,000$25.28$429,760.00View SEC Filing  
3/20/2015Sunil PatelInsiderSell18,000$27.76$499,680.00View SEC Filing  
3/17/2015Austin GurneyInsiderSell4,000$27.37$109,480.00View SEC Filing  
2/5/2015Timothy HoeySVPSell7,500$22.83$171,225.00View SEC Filing  
2/2/2015John A LewickiEVPSell4,000$22.49$89,960.00View SEC Filing  
1/20/2015Austin GurneyInsiderSell4,000$22.87$91,480.00View SEC Filing  
1/12/2015Jakob DupontSVPSell1,500$25.89$38,835.00View SEC Filing  
1/5/2015Jakob DupontSVPSell7,500$23.00$172,500.00View SEC Filing  
1/2/2015John A LewickiEVPSell4,000$22.10$88,400.00View SEC Filing  
12/31/2014Denise Pollard-KnightDirectorSell3,799$21.66$82,286.34View SEC Filing  
12/30/2014Denise Pollard-KnightDirectorSell17,607$21.63$380,839.41View SEC Filing  
12/18/2014Jonathan D RootDirectorSell13,052$21.05$274,744.60View SEC Filing  
12/17/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
12/10/2014Denise Pollard-KnightDirectorSell32,940$21.78$717,433.20View SEC Filing  
12/9/2014Denise Pollard-KnightDirectorSell23,273$21.78$506,885.94View SEC Filing  
12/8/2014Denise Pollard-KnightDirectorSell1,727$21.68$37,441.36View SEC Filing  
12/5/2014Denise Pollard-KnightDirectorSell25,000$21.60$540,000.00View SEC Filing  
12/1/2014John A LewickiEVPSell4,000$21.19$84,760.00View SEC Filing  
11/5/2014Timothy HoeySVPSell2,500$19.51$48,775.00View SEC Filing  
10/29/2014Paul J HastingsCEOSell16,769$21.99$368,750.31View SEC Filing  
10/2/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
10/2/2014John A LewickiEVPSell5,809$20.00$116,180.00View SEC Filing  
9/4/2014Jack W LasersohnDirectorBuy3,170$18.35$58,169.50View SEC Filing  
9/3/2014Jack W LasersohnDirectorBuy3,000$18.40$55,200.00View SEC Filing  
9/2/2014John A LewickiEVPSell2,191$20.01$43,841.91View SEC Filing  
8/22/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
8/21/2014Deepika PakianathanDirectorBuy80,203$18.98$1,522,252.94View SEC Filing  
8/15/2014Jack W LasersohnDirectorBuy1,045$17.00$17,765.00View SEC Filing  
8/5/2014Timothy HoeySVPSell2,500$21.66$54,150.00View SEC Filing  
8/1/2014John A LewickiEVPSell4,000$20.98$83,920.00View SEC Filing  
7/29/2014Paul J HastingsCEOSell16,770$22.11$370,784.70View SEC Filing  
7/23/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
7/17/2014Austin GurneyInsiderSell4,000$20.46$81,840.00View SEC Filing  
7/1/2014John A LewickiEVPSell4,000$23.86$95,440.00View SEC Filing  
6/30/2014Denise Pollard-KnightDirectorSell11,485$23.59$270,931.15View SEC Filing  
6/26/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
6/25/2014Denise Pollard-KnightDirectorSell3,252$23.56$76,617.12View SEC Filing  
6/24/2014Denise Pollard-KnightDirectorSell64,561$24.08$1,554,628.88View SEC Filing  
6/17/2014Austin GurneyInsiderSell4,000$24.99$99,960.00View SEC Filing  
6/16/2014John A LewickiEVPSell4,000$24.59$98,360.00View SEC Filing  
6/10/2014Presidio Management Group ViiiMajor ShareholderSell13,052$24.57$320,687.64View SEC Filing  
5/12/2014Presidio Management Group Viiimajor shareholderSell46,327$21.99$1,018,730.73View SEC Filing  
7/23/2013Denise Pollard-KnightDirectorBuy58,824$17.00$1,000,008.00View SEC Filing  
7/23/2013Presidio Management Group ViiiMajor ShareholderBuy158,823$17.00$2,699,991.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Oncomed Pharmaceuticals (NASDAQ OMED) News Headlines

Source:
DateHeadline
Oncomed Pharmaceuticals (OMED) & Its Rivals Critical AnalysisOncomed Pharmaceuticals (OMED) & Its Rivals Critical Analysis
www.americanbankingnews.com - December 13 at 5:38 PM
$5.10 Million in Sales Expected for Oncomed Pharmaceuticals Inc (OMED) This Quarter$5.10 Million in Sales Expected for Oncomed Pharmaceuticals Inc (OMED) This Quarter
www.americanbankingnews.com - December 8 at 12:56 PM
Oncomed Pharmaceuticals (OMED) and Its Competitors Financial ContrastOncomed Pharmaceuticals (OMED) and Its Competitors Financial Contrast
www.americanbankingnews.com - December 6 at 7:25 PM
OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman ResponsibilitiesOncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman Responsibilities
finance.yahoo.com - December 6 at 10:32 AM
Critical Analysis: Oncomed Pharmaceuticals (OMED) & Its PeersCritical Analysis: Oncomed Pharmaceuticals (OMED) & Its Peers
www.americanbankingnews.com - December 6 at 8:04 AM
OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman ... - GlobeNewswire (press release)OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman ... - GlobeNewswire (press release)
globenewswire.com - November 28 at 10:27 AM
Head-To-Head Comparison: OncoMed Pharmaceuticals (OMED) & Its RivalsHead-To-Head Comparison: OncoMed Pharmaceuticals (OMED) & Its Rivals
www.americanbankingnews.com - November 25 at 1:16 PM
$5.10 Million in Sales Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter$5.10 Million in Sales Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - November 20 at 6:50 AM
OncoMed Pharmaceuticals, Inc. (OMED) Receives Consensus Rating of "Hold" from BrokeragesOncoMed Pharmaceuticals, Inc. (OMED) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 20 at 5:38 AM
OncoMed Pharmaceuticals, Inc. (OMED) Expected to Announce Earnings of -$0.31 Per ShareOncoMed Pharmaceuticals, Inc. (OMED) Expected to Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - November 18 at 3:30 PM
OncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017OncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 9 at 10:08 AM
ETFs with exposure to OncoMed Pharmaceuticals, Inc. : November 8, 2017ETFs with exposure to OncoMed Pharmaceuticals, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 10:08 AM
Equities Analysts Offer Predictions for OncoMed Pharmaceuticals, Inc.s FY2017 Earnings (OMED)Equities Analysts Offer Predictions for OncoMed Pharmaceuticals, Inc.'s FY2017 Earnings (OMED)
www.americanbankingnews.com - November 8 at 10:54 AM
OncoMed Pharmaceuticals (OMED) CEO Sunil Patel on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaOncoMed Pharmaceuticals' (OMED) CEO Sunil Patel on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 6 at 4:58 AM
OncoMed Pharmaceuticals, Inc. to Host Earnings CallOncoMed Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 8:24 AM
OncoMed Pharmaceuticals, Inc. to Host Earnings CallOncoMed Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 8:24 AM
OncoMed Announces Third Quarter 2017 Financial Results and Operational HighlightsOncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights
finance.yahoo.com - November 4 at 8:24 AM
OncoMed Announces Third Quarter 2017 Financial Results and Operational HighlightsOncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights
finance.yahoo.com - November 4 at 8:24 AM
OncoMed reports 3Q lossOncoMed reports 3Q loss
finance.yahoo.com - November 4 at 8:24 AM
OncoMed reports 3Q lossOncoMed reports 3Q loss
finance.yahoo.com - November 4 at 8:24 AM
Edited Transcript of OMED earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of OMED earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 8:24 AM
Edited Transcript of OMED earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of OMED earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 8:24 AM
OncoMed Pharmaceuticals, Inc. (OMED) Posts  Earnings Results, Beats Expectations By $0.13 EPSOncoMed Pharmaceuticals, Inc. (OMED) Posts Earnings Results, Beats Expectations By $0.13 EPS
www.americanbankingnews.com - November 3 at 7:02 PM
 Analysts Expect OncoMed Pharmaceuticals, Inc. (OMED) Will Announce Quarterly Sales of $6.25 Million Analysts Expect OncoMed Pharmaceuticals, Inc. (OMED) Will Announce Quarterly Sales of $6.25 Million
www.americanbankingnews.com - October 31 at 10:40 AM
OncoMed Pharmaceuticals Inc (OMED): Is Now The Time To Bet On Healthcare?OncoMed Pharmaceuticals Inc (OMED): Is Now The Time To Bet On Healthcare?
finance.yahoo.com - October 28 at 11:24 AM
OncoMed Pharmaceuticals, Inc. (OMED) Receives Consensus Recommendation of "Hold" from AnalystsOncoMed Pharmaceuticals, Inc. (OMED) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 26 at 8:34 AM
OncoMed Pharmaceuticals to Report Third Quarter Financial Results and Operational Highlights on November 2nd, 2017OncoMed Pharmaceuticals to Report Third Quarter Financial Results and Operational Highlights on November 2nd, 2017
finance.yahoo.com - October 25 at 8:35 AM
OncoMed Pharmaceuticals, Inc. (OMED) Set to Announce Quarterly Earnings on MondayOncoMed Pharmaceuticals, Inc. (OMED) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 23 at 11:48 AM
OncoMed Pharmaceuticals, Inc. (OMED) Downgraded by Zacks Investment ResearchOncoMed Pharmaceuticals, Inc. (OMED) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 15 at 11:32 PM
$6.25 Million in Sales Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter$6.25 Million in Sales Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - October 11 at 5:20 AM
 Brokerages Expect OncoMed Pharmaceuticals, Inc. (OMED) to Announce -$0.39 Earnings Per Share Brokerages Expect OncoMed Pharmaceuticals, Inc. (OMED) to Announce -$0.39 Earnings Per Share
www.americanbankingnews.com - October 9 at 10:24 PM
OncoMed Pharmaceuticals, Inc. (OMED) Lifted to Buy at Zacks Investment ResearchOncoMed Pharmaceuticals, Inc. (OMED) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - October 8 at 10:36 PM
OncoMed Pharmaceuticals (OMED) Hold Rating Reiterated at SunTrust Banks, Inc.OncoMed Pharmaceuticals' (OMED) Hold Rating Reiterated at SunTrust Banks, Inc.
www.americanbankingnews.com - October 7 at 12:00 PM
What You Must Know About OncoMed Pharmaceuticals Inc’s (OMED) RisksWhat You Must Know About OncoMed Pharmaceuticals Inc’s (OMED) Risks
finance.yahoo.com - October 2 at 8:16 PM
Oncomed Pharmaceuticals Inc (OMED) Given Average Recommendation of "Hold" by BrokeragesOncomed Pharmaceuticals Inc (OMED) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 1 at 6:42 AM
Jefferies Group LLC Reiterates Buy Rating for OncoMed Pharmaceuticals, Inc. (OMED)Jefferies Group LLC Reiterates Buy Rating for OncoMed Pharmaceuticals, Inc. (OMED)
www.americanbankingnews.com - September 28 at 8:00 AM
-$0.39 Earnings Per Share Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter-$0.39 Earnings Per Share Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - September 21 at 8:52 AM
BRIEF-OncoMed CEO Paul Hastings to take medical leave of absenceBRIEF-OncoMed CEO Paul Hastings to take medical leave of absence
www.reuters.com - September 20 at 7:17 AM
As company fortunes shift, hard-charging Peninsula CEO takes medical leaveAs company fortunes shift, hard-charging Peninsula CEO takes medical leave
www.bizjournals.com - September 20 at 7:17 AM
OncoMed Pharmaceuticals, Inc. (OMED) Receives Hold Rating from Cantor FitzgeraldOncoMed Pharmaceuticals, Inc. (OMED) Receives Hold Rating from Cantor Fitzgerald
www.americanbankingnews.com - September 19 at 11:24 AM
OncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of AbsenceOncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence
feeds.benzinga.com - September 19 at 8:48 AM
OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial - GlobeNewswire (press release)OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial - GlobeNewswire (press release)
globenewswire.com - September 14 at 8:47 AM
OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical TrialOncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial
finance.yahoo.com - September 14 at 8:47 AM
OncoMed Pharmaceuticals, Inc. (OMED) Receives Consensus Rating of "Hold" from AnalystsOncoMed Pharmaceuticals, Inc. (OMED) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - September 6 at 6:40 AM
 Analysts Anticipate OncoMed Pharmaceuticals, Inc. (OMED) Will Announce Earnings of -$0.39 Per Share Analysts Anticipate OncoMed Pharmaceuticals, Inc. (OMED) Will Announce Earnings of -$0.39 Per Share
www.americanbankingnews.com - September 2 at 4:10 PM
ETFs with exposure to OncoMed Pharmaceuticals, Inc. : August 31, 2017ETFs with exposure to OncoMed Pharmaceuticals, Inc. : August 31, 2017
finance.yahoo.com - September 1 at 6:47 AM
Reviewing OncoMed Pharmaceuticals (OMED) and Aptose Biosciences (APTO)Reviewing OncoMed Pharmaceuticals (OMED) and Aptose Biosciences (APTO)
www.americanbankingnews.com - August 31 at 2:26 AM
OncoMed Pharmaceuticals, Inc. (OMED) Given a $5.00 Price Target at Jefferies Group LLCOncoMed Pharmaceuticals, Inc. (OMED) Given a $5.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - August 26 at 8:16 AM
OncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017OncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 7:59 AM
 Analysts Anticipate OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to Announce -$0.38 EPS Analysts Anticipate OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to Announce -$0.38 EPS
www.americanbankingnews.com - August 15 at 6:32 AM

SEC Filings

Oncomed Pharmaceuticals (NASDAQ:OMED) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Oncomed Pharmaceuticals (NASDAQ:OMED) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Oncomed Pharmaceuticals (NASDAQ OMED) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.